PPC
ARQT icon

Park Place Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Park Place Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-183
Closed -$1.7K – 815
2024
Q3 		$1.7K Hold
183
– – ﹤0.01% 785
2024
Q2 		$1.7K Hold
183
– – ﹤0.01% 791
2024
Q1 		$1.81K Buy
+183
New +$1.37K ﹤0.01% 840
2023
Q4 		– Sell
-197
Closed -$1.05K – 867
2023
Q3 		$1.05K Hold
197
– – ﹤0.01% 980
2023
Q2 		$1.88K Hold
197
– – ﹤0.01% 947
2023
Q1 		$2.17K Buy
197
+95
+93% +$1.37K ﹤0.01% 939
2022
Q4 		$2K Buy
+102
New +$1.78K ﹤0.01% 934

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Park Place Capital's ARQT Position: Q4 2024 in Review

Park Place Capital sold out of Arcutis Biotherapeutics (ARQT) in Q4 2024, closing a stake of 183 shares — an estimated $1.7K sold.

Park Place Capital first reported a position in ARQT in Q4 2022 and held it in 7 quarters. The position peaked at $2.17K in Q1 2023. 208 funds tracked by Wall St. Rank hold ARQT as of Q4 2024.

  • Park Place Capital reported no remaining Arcutis Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Park Place Capital sold 183 Arcutis Biotherapeutics shares in Q4 2024, an estimated $1.7K.
  • Park Place Capital first reported a position in Arcutis Biotherapeutics in Q4 2022 and held it in 7 quarters.
  • Park Place Capital's Arcutis Biotherapeutics position peaked at $2.17K in Q1 2023.
  • 208 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2024.

Based on Park Place Capital's 13F filing for Q4 2024, filed 17 Jan 2025.